Market Research Logo

Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Pipeline Review, H2 2016

Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Pipeline Review, H2 2016’, provides in depth analysis on Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) targeted pipeline therapeutics.

The report provides comprehensive information on the Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1)
  • The report reviews Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) Overview
Therapeutics Development
Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Products under Development by Stage of Development
Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Products under Development by Therapy Area
Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Products under Development by Indication
Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Pipeline Products Glance
Late Stage Products
Early Stage Products
Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Products under Development by Companies
Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Therapeutics Assessment
Assessment by Monotherapy/Combination Products
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Companies Involved in Therapeutics Development
Daiichi Sankyo Company, Limited
Intellipharmaceutics International Inc.
Mapi Pharma Ltd.
Pfizer Inc.
Prismic Pharmaceuticals, Inc.
Yuhan Corporation
Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Drug Profiles
(palmidrol + pregabalin) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
gabapentin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mirogabalin besylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NVA-1309 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pregabalin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pregabalin CR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pregabalin CR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pregabalin ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pregabalin IR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pregabalin XR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Dormant Projects
Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Discontinued Products
Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Featured News & Press Releases
Jan 11, 2016: Pfizer Voluntarily Recalls Lyrica Capsules
Nov 25, 2015: Pfizer Reports Top-Line Results from a Phase 3 Study of LYRICA (pregabalin) Capsules CV in Adults with Post-Traumatic Peripheral Neuropathic Pain
Sep 10, 2015: Actavis Wins Patent Case Over Generic Lyrica
Mar 30, 2015: Intellipharmaceutics Submits and was Granted a Pre-IND Meeting Request with the US FDA for Its Regabatin XR (Pregabalin Extended Release Capsules) Drug Candidate
Mar 12, 2015: Pfizer Reports Top-Line Results From A Phase 4 Study Evaluating LYRICA Capsules CV As A Treatment For Adolescents With Fibromyalgia
Feb 04, 2015: Daiichi Sankyo Announces First Patients in Large-scale, Multi-national Phase 3 Clinical Programs for Mirogabalin
Dec 18, 2014: Pfizer Reports Top-Line Results From a Phase 3 Study Evaluating Pregabalin Controlled-Release Formulation as a Treatment for Patients With Postherpetic Neuralgia
Dec 10, 2014: Commonly Prescribed Drug for Lower Back Pain Not Effective
Nov 12, 2014: Pfizer to present data on LYRICA (pregabalin) capsules at ACR 2014 Annual Meeting
Nov 10, 2014: US Court Issues Final Order and Judgment Approving Class Action Settlement Related To Neurontin
Oct 22, 2014: Intellipharmaceutics Reports Positive Results from a Series of Phase I Clinical Trials of Regabatin XR (Pregabalin Extended-Release)
Aug 12, 2014: Pfizer Reports Top-line Results from Postherpetic Neuralgia and Painful Diabetic Peripheral Neuropathy Lyrica Studies Conducted in China
Jun 02, 2014: Pfizer Agrees To Pay $325m To Settle Neurontin Case
Feb 21, 2014: Pfizer's Pregabalin Receives CHMP Positive Opinion
Dec 09, 2013: US Supreme Court Refuses To Hear Pfizer's Appeal On Marketing Of Neurontin
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Indication, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Number of Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Pipeline by Daiichi Sankyo Company, Limited, H2 2016
Pipeline by Intellipharmaceutics International Inc., H2 2016
Pipeline by Mapi Pharma Ltd., H2 2016
Pipeline by Pfizer Inc., H2 2016
Pipeline by Prismic Pharmaceuticals, Inc., H2 2016
Pipeline by Yuhan Corporation, H2 2016
Dormant Projects, H2 2016
Discontinued Products, H2 2016
List of Figures
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Indication, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report